Investment Rating - The investment rating for Dong'e Ejiao is maintained as "Buy" [1] Core Views - The company achieved a revenue of 1.719 billion yuan in Q1 2025, representing a year-on-year increase of 18.24%. The net profit attributable to the parent company was 425 million yuan, up 20.25% year-on-year. The non-recurring net profit was 416 million yuan, reflecting a growth of 26.69% year-on-year [4][5] - The gross margin for Q1 2025 was 73.62%, an increase of 1.83 percentage points, while the net profit margin was 24.73%, up 0.40 percentage points [4] - The company is optimistic about its long-term growth potential due to its focus on the Ejiao category, male health products, and industry chain layout. Profit forecasts for 2025-2027 are set at 1.874 billion, 2.248 billion, and 2.679 billion yuan respectively, with EPS projected at 2.91, 3.49, and 4.16 yuan [4][5] Financial Performance Summary - In Q1 2025, the company reported a negative net cash flow from operating activities of -304 million yuan, primarily due to an increase in accounts receivable and financing receivables. Accounts receivable rose to 541 million yuan, a year-on-year increase of 583.32% [5] - The company is expected to manage its credit limits effectively throughout the year, which should alleviate short-term cash flow pressures [5] - The financial summary indicates a steady growth trajectory with revenue projections of 6.919 billion yuan for 2025, 8.075 billion yuan for 2026, and 9.313 billion yuan for 2027, with corresponding net profits of 1.874 billion, 2.248 billion, and 2.679 billion yuan [8][10] Strategic Initiatives - The company is actively deepening the integration of primary, secondary, and tertiary industries to enhance growth. It focuses on securing raw material supply, advancing the Ejiao main business, and developing a dual-driven model of pharmaceuticals and health consumer products [6] - The strategy includes building a strong brand matrix and integrating online and offline channels to enhance market presence [6]

医药生物/中药Ⅱ 余汝意（分析师） 巢舒然（联系人） yuruyi@kysec.cn 证书编号：S0790523070002 chaoshuran@kysec.cn 证书编号：S0790123110015 东阿阿胶（000423.SZ） 一季度业绩稳增，现金流短期承压不改长期向好信心 2025 年 04 月 30 日 投资评级：买入（维持） | 日期 | 2025/4/29 | | --- | --- | | 当前股价(元) | 54.00 | | 一年最高最低(元) | 72.91/44.62 | | 总市值(亿元) | 347.75 | | 流通市值(亿元) | 347.75 | | 总股本(亿股) | 6.44 | | 流通股本(亿股) | 6.44 | | 近 3 个月换手率(%) | 60.45 | 股价走势图 -40% -20% 0% 20% 40% 2024-04 2024-08 2024-12 东阿阿胶 沪深300 数据来源：聚源 相关研究报告 《经营业绩增速亮眼，2025 年深化产 业布局突破发展—公司信息更新报 告》-2025.3.19 《"药品+健康消费品"双轮驱动，滋 补品牌焕新生—公 ...

Group 1 - The China Securities 500 Quality Growth Index (930939) has shown a slight increase of 0.22% as of April 30, 2025, with notable gains in constituent stocks such as Amlogic (688099) up 4.29% and Anker Innovations (300866) up 3.80% [1] - The 500 Quality Growth ETF (560500) has also risen by 0.22%, with the latest price reported at 0.92 yuan, and a significant increase in shares by 5 million this month, ranking it in the top third among comparable funds [1] - Huaxi Securities highlights the role of the Chinese version of the stabilization fund in supporting the A-share market, emphasizing a higher positioning for "stabilizing and activating the stock market" compared to previous times [1] Group 2 - The 500 Quality Growth ETF closely tracks the China Securities 500 Quality Growth Index, which selects 100 companies with high profitability, sustainable earnings, and strong cash flow from the broader 500 Index [2] - As of March 31, 2025, the top ten weighted stocks in the index include Chifeng Jilong Gold Mining (600988) and Ninebot (689009), with the top ten stocks accounting for a total weight of 24.26% [2]

证 券 研 究 报 告 东阿阿胶（000423）2025 年一季报点评 推荐（维持） 勿因短期现金流而低估经营韧性 目标价：72.5 元 事项： 公司公告 1Q25 实现收入 17.2 亿元（+18.2% yoy）、归母净利 4.3 亿元（+20.2% yoy）、扣非净利 4.2 亿元（+26.7% yoy），并召开一季度业绩说明会，对市场较 为关注的现金流及应收账款等财务指标变化进行解读。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 5,921 | 6,919 | 8,022 | 9,191 | | 同比增速(%) | 25.6% | 16.9% | 15.9% | 14.6% | | 归母净利润(百万) | 1,557 | 1,869 | 2,205 | 2,602 | | 同比增速(%) | 35.3% | 20.0% | 18.0% | 18.0% | | 每股盈利(元) | 2.42 | 2.90 | 3.42 | ...

Core Insights - Dong-E E-Jiao achieved strong performance in Q1 2025, with revenue of 1.719 billion yuan, a year-on-year increase of 18.24%, and a net profit of 425 million yuan, up 20.25% [1][2] - The company continues to implement a dual-driven strategy of "pharmaceuticals + health consumer products," contributing to its robust growth [2][3] - The gross profit margin improved significantly from 47.57% in 2019 to 73.63% in Q1 2025, driven by digital supply chain upgrades and a focus on high-margin products [1][2] Financial Performance - In Q1 2025, the company reported a net profit of 425 million yuan, with a non-recurring net profit of 416 million yuan, reflecting a growth of 26.69% [2] - Compared to Q4 2024, revenue increased by 7.98% and net profit grew by 4.93% [2] - The sales expense ratio decreased by 2.6 percentage points to 36.26%, while the management expense ratio stood at 5.04%, indicating effective cost control [2] Product Development - Dong-E E-Jiao is expanding into the men's health supplement market, introducing products like brain and kidney tonics, and has plans for further innovation [3] - The company continues to lead the OTC market with its core product, Dong-E E-Jiao blocks, and has seen strong sales in innovative products like instant dissolvable E-Jiao powder and ready-to-eat freeze-dried E-Jiao series [2][3] Strategic Moves - The company is divesting its 15% stake in China National Pharmaceutical Group Jinan, indicating a strategic focus on its core business of E-Jiao and related products [3] - Dong-E E-Jiao aims to solidify its position as the leading brand in health supplements by concentrating resources on its main business [3] Research and Development - Over the past five years, Dong-E E-Jiao has invested 787 million yuan in R&D, with annual expenditures showing a consistent commitment to innovation [4][5] - The company has established a collaborative innovation platform, focusing on developing high-quality health products and traditional Chinese medicine [5]

Core Viewpoint - Dong'e Ejiao reported strong revenue and profit growth in Q1 2025, but faced challenges in cash flow management and accounts receivable [2][5][6] Business Overview - In Q1 2025, Dong'e Ejiao achieved total revenue of 1.719 billion yuan, an increase of 18.24% year-on-year; net profit attributable to shareholders reached 425 million yuan, up 20.25% year-on-year; and net profit excluding non-recurring items was 416 million yuan, a rise of 26.69% year-on-year [2] Profitability - The company's gross margin reached 73.62%, an increase of 2.55 percentage points year-on-year; net margin was 24.73%, up 1.66 percentage points year-on-year, indicating effective cost control and enhanced product value [3] Cost Control - Total selling, administrative, and financial expenses amounted to 693 million yuan, accounting for 40.31% of total revenue, a decrease of 2.13 percentage points compared to the same period last year, reflecting progress in cost management [4] Cash Flow and Financial Position - Operating cash flow per share was -0.47 yuan, a significant decrease of 147.63% compared to 0.99 yuan in the same period last year; cash and cash equivalents fell from 6.791 billion yuan to 5.432 billion yuan, a year-on-year decrease of 20.02%; accounts receivable increased from 187 million yuan to 541 million yuan, a rise of 190.08%, indicating challenges in cash flow management and accounts receivable collection [5] Summary - Overall, Dong'e Ejiao demonstrated strong profitability in Q1 2025 but faces pressure in cash flow management and accounts receivable, necessitating close monitoring of future cash flow improvement measures and accounts receivable management [6]

Investment Rating - The investment rating for Dong'e Ejiao is "Buy" (maintained) [1] Core Views - The company's Q1 2025 performance met expectations, with total revenue of 1.719 billion yuan, representing a year-on-year growth of 18.24%. The net profit attributable to shareholders was 425 million yuan, up 20.25% year-on-year [9] - The company's product lines, particularly the Ejiao series, are experiencing steady growth, with various marketing strategies being employed to enhance sales and reach target demographics [9] - The company has initiated a mid-term dividend distribution, with a high dividend payout ratio of 99.7% in 2024, reflecting its commitment to returning value to shareholders [9] - The forecast for net profit attributable to shareholders for 2025-2027 is 1.864 billion, 2.215 billion, and 2.565 billion yuan respectively, with corresponding P/E ratios of 19, 16, and 14 [9] Financial Summary - Total revenue is projected to grow from 5.921 billion yuan in 2024 to 8.918 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 13.47% [1] - The net profit attributable to shareholders is expected to increase from 1.557 billion yuan in 2024 to 2.565 billion yuan in 2027, with a CAGR of approximately 15.83% [1] - The latest diluted EPS is forecasted to rise from 2.42 yuan in 2024 to 3.98 yuan in 2027 [1] - The company's return on equity (ROE) improved to 4.04% in Q1 2025, with a gross margin of 73.62% and a net profit margin of 24.73% [9]

Market Overview - On April 28, the Shanghai Composite Index fell by 0.2%, the Shenzhen Component Index decreased by 0.62%, and the ChiNext Index dropped by 0.65% [2] - A total of 58 stocks appeared on the "Dragon and Tiger List" due to significant price movements, with the highest net inflow of funds into Dawi Technology (600589.SH) amounting to 123 million yuan [2][4] Stock Performance - Dawi Technology saw a closing price increase of 10.06% with a turnover rate of 12.15%, and it accounted for 9.85% of the total trading volume [4][6] - The stock with the highest net outflow was Dong'e Ejiao (000423.SZ), which experienced a net sell-off of 360 million yuan, representing 22.56% of its total trading volume, and closed down by 10% [6][10] Institutional Activity - Among the 33 stocks on the Dragon and Tiger List, institutions were net sellers of 405 million yuan, buying 18 stocks and selling 15 [6][11] - The stock with the highest net purchase by institutions was Hongjing Optoelectronics (301479.SZ), which rose by 20% and had a turnover rate of 32.24% [7] Northbound Capital Flow - Northbound funds participated in 10 stocks on the Dragon and Tiger List, with a total net outflow of 116 million yuan [10] - Dawi Technology had the highest net inflow from northbound funds, amounting to 53.44 million yuan, while Dong'e Ejiao faced the largest net outflow of 93.92 million yuan [10][11] Summary of Key Stocks - Dawi Technology: +10.06%, net buy of 123 million yuan, turnover rate of 12.15% [4][6] - Dong'e Ejiao: -10%, net sell of 360 million yuan, turnover rate of 4.43% [6][10] - Hongjing Optoelectronics: +20%, highest institutional net buy [7] - Northbound funds showed mixed activity with Dawi Technology and Dong'e Ejiao [11]

东阿阿胶（000423）今日逼近跌停，成交额15.98亿元，换手率4.43%，盘后龙虎榜数据显示，深股通专 用席位买入8601.85万元并卖出1.80亿元，1家机构专用席位净买入3402.36万元，有4家机构专用席位净 卖出3.60亿元。 ...

Group 1: Financial Performance - The company reported a revenue of 1.719 billion yuan in Q1 2025, representing a year-on-year growth of 18.24% [1] - Net profit attributable to shareholders reached 425 million yuan, with a year-on-year increase of 20.25% [1] - The gross margin improved by 2.43 percentage points to 73.62% compared to the previous year [1] Group 2: Strategic Initiatives - The company is implementing a dual-driven strategy of "pharmaceuticals + health consumer products," maintaining a positive growth trend across its core products [2] - R&D investment in Q1 amounted to 39 million yuan, supporting the development of new products aligned with consumer trends [2] - The company is enhancing its tourism framework by integrating various cultural and health-related experiences, aiming to create a unique model for traditional Chinese medicine tourism [2] Group 3: Market Position and Opportunities - The dual-driven strategy is effectively modernizing the brand and expanding its consumer base, capitalizing on policy benefits and consumption upgrades in the traditional Chinese medicine sector [3] - The collaboration with China Resources Group has revitalized the company through strategic restructuring and resource integration, enhancing its competitive edge [4] - The establishment of a stock incentive plan marks a significant organizational change, expected to boost operational momentum and align with long-term performance goals [5]